Fc Receptor Binding Reduction Before Antibody Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapies and therapeutic agents are hindered by the binding of IgG molecules to Fc receptors, which competes for receptor binding sites, reducing their efficacy, especially in autoimmune conditions and organ transplantation.
Innovation Solution
Administer an agent that reduces Fc receptor binding of serum IgG molecules, followed by a therapy or therapeutic agent after a sufficient time interval to eliminate Fc receptor binding, creating a window for enhanced efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic antibodies are administered to treat disease, then therapeutic benefit is provided, but endogenous IgG molecules compete for Fc receptor binding sites, reducing the efficacy of the therapeutic antibody
Solution Approach 1:
The patent applies preliminary action by administering an agent (such as an FcRn antagonist or IgG-depleting antibody) before administering the therapeutic antibody. This preliminary step reduces or eliminates endogenous IgG levels and Fc receptor binding competition, creating a favorable environment for the subsequent therapeutic antibody to bind effectively to Fc receptors and exert its therapeutic effect.
Solution Approach 2:
The patent employs preliminary anti-action by using agents that specifically counteract the harmful Fc receptor binding of endogenous IgG molecules. Examples include FcRn antagonists that block IgG recycling and IgG-depleting antibodies that remove endogenous IgG from circulation, thereby preventing the competitive inhibition that would otherwise reduce therapeutic antibody efficacy.
2Reliability
If Fc receptor binding by endogenous IgG is reduced to enhance therapeutic antibody efficacy, then a time interval is required between administering the agent and the therapy, which delays treatment
Solution Approach 1:
The patent applies parameter changes by modifying the pharmacokinetic parameters of IgG through the use of specific agents. FcRn antagonists alter the half-life and clearance rate of IgG, while IgG-depleting antibodies change the concentration and binding capacity of endogenous IgG. These parameter changes allow for optimized timing of therapeutic antibody administration, balancing the need for reduced Fc receptor competition with minimizing treatment delay.
3Reliability
If agents that reduce Fc receptor binding are administered, then therapeutic benefit is improved, but additional treatment steps and complexity are introduced to the therapy regimen
Solution Approach 1:
The patent applies merging by combining the administration of the IgG-reducing agent and the therapeutic antibody into a coordinated treatment regimen. In some embodiments, these agents are administered in close temporal proximity or as part of a unified therapeutic protocol, simplifying the overall treatment process while maintaining the beneficial effects of reduced Fc receptor competition.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances the efficacy of therapeutic antibodies and allows otherwise ineffective therapies, such as organ transplantation, by eliminating competition for Fc receptor binding, and reduces the effect of pathogenic autoantibodies.
Implementation Method 1
administering to the subject an agent which reduces Fc receptor binding of serum IgG molecules in the subject
Data Source
AI summary
The invention relates to a method for improving the benefit of a therapy or therapeutic agent to a subject. The method comprises administering to the subject an agent which reduce Fc receptor binding of serum IgG molecules in the subject; and subsequently administering said therapy or therapeutic agent to the subject. The invention also related to a method for administering to the subject an agent which reduces Fc receptor binding of serum IgG molecules in the subject and optionally (b) subsequently subjecting the subject to a treatment which removes endogenous autoantibodies. The invention also relates to a kit for carrying out a method of the invention.